Shots: The P-III DAPA-HF study involves assessing of Farxiga (10mg) vs PBO in addition to SOC in patients with HF and reduced ejection fraction (LVEF ≤ 40%) with/out T2D The […]readmore
Tags : DAPA-HF
Shots: The P-III DAPA-HF study involves assessing of Farxiga (10mg, qd) vs PBO in patients with heart failure and reduced ejection fraction (HFrEF) (LVEF ≤ 40%), with/without type-2 diabetes on […]readmore